Daewoong Therapeutics (CEO Bokki Kang), a subsidiary of Daewoong Pharmaceutical, has completed preclinical studies and compiled data for a microneedle patch within the Semaglutide series, a GLP-1 analogue, using its proprietary 'CLOPAM' (Closed-Packed Aeroperssured Microneedle) platform
The 87% success rate for achieving A1C below 7.0% exceeds what most diabetes medications accomplish as monotherapy
Yes, all treatments are administered by trained medical professionals following strict safety protocols
The 29-gauge hits the sweet spot between comfort and function for most body types
The branded drug (Egrifta) is FDA-approved only for HIV-associated lipodystrophy
"Never did the GLP-1, but I don't judge nobody who does it," he said